HeartBeam, Inc. (BEAT) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reveals strong financial discipline, a strategic focus on high-net-worth markets, and promising product development with AI collaborations. Despite some uncertainty in patient numbers and study timelines, the Q&A indicates positive sentiment towards the subscription model and revenue potential. The recent financing strengthens the company's financial position. The overall sentiment is positive, with expectations of reaching breakeven and significant revenue scaling, suggesting a stock price increase of 2-8% over the next two weeks.
Key Financial Performance
Net Loss $4.7 million, a 19% decrease in operating cash outflow compared to the same quarter in the prior year. This reduction is attributed to judicious timing of investments and maintaining a low-cost profile.
Net Cash Used in Operating Activities $3.6 million, a 19% decrease year-over-year. This reflects the company's ability to execute milestones while reducing expenditures.
Cash Balance (March 31, 2026) $2 million, with a pro forma cash balance of approximately $12.4 million after including net proceeds from a recent $11.5 million financing. This financing strengthens the financial position and provides runway into 2027.
Cash Outflow Expectations for 2026 Estimated below $16 million, revised from $17-$19 million due to a leaner sales team approach. This reflects a focus on financial discipline and efficient resource allocation.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
HeartBeam System: Developed the first-ever portable cable-free ECG that synthesizes a 12-lead ECG. Received two FDA clearances for arrhythmia assessment. Embarked on a limited commercial launch with positive reception among physicians.
12-lead Patch: Completed a working prototype and initiated a pilot study focused on ischemia detection. Positioned to disrupt the $2 billion ambulatory cardiac monitoring market with its unique capabilities.
Commercial Partnerships: Signed partnerships with ClearCardio and Atelier Health, establishing flagship accounts in New York City, Dallas, South Florida, and Southern California. Targeting the Direct Pay segment with a potential market of 5 million U.S. patients.
Financial Position: Strengthened financial position with $11.5 million financing, providing a cash runway into 2027. Reduced operating cash outflow by 19% year-over-year in Q1 2026.
Commercial Launch Strategy: Focused on validating premium value proposition, refining workflows, and scaling efficiently with a lean team. Plans to expand sales and clinical teams in 2027.
AI Collaboration: Announced a strategic collaboration with Mount Sinai to develop next-generation algorithms for heart attack detection and personalized cardiac assessment.
Heart Attack Detection: Initiated the ALIGN-ACS pilot study in Europe, comparing HeartBeam ECG to standard 12-lead ECG for heart attack detection. Enrollment is ahead of schedule.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Clinical Validation Risks: The company is pursuing FDA indication expansion for its HeartBeam system and 12-lead patch. Delays or failures in clinical trials, such as the ALIGN-ACS pilot study or the ischemia detection pilot study, could hinder regulatory approval and market entry.
Commercialization Challenges: The limited commercial launch relies on a lean team and flagship accounts in four geographies. Any issues in scaling operations, onboarding accounts, or achieving deep adoption could impact revenue and growth targets.
Competitive Market Pressures: The ambulatory cardiac monitoring market is highly competitive, with existing players offering long-term continuous monitors and mobile cardiac telemetry. HeartBeam's ability to differentiate its 12-lead patch and gain market share is critical.
Financial Sustainability: The company has a cash runway into 2027 but is dependent on achieving commercialization milestones and customer adoption to sustain operations. Any delays in revenue generation could strain financial resources.
Technological and Product Development Risks: The success of the 12-lead patch and AI algorithms depends on technological advancements and integration into existing workflows. Failures in product development or unmet performance expectations could impact adoption.
Partnership and Collaboration Risks: The company is in discussions with industry players for partnerships to bring the 12-lead patch to market. Delays or failures in securing these partnerships could slow market entry and adoption.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Commercialization Goals: In the first half of 2026, the company is focused on validating its premium value proposition, refining systems and processes, signing and onboarding anchor accounts, and proving the scale and efficiency of the model. In the second half of 2026, the focus will shift to proving deep adoption inside anchor accounts, establishing a funnel for 2027 revenue and adoption goals, developing white papers and clinical proof points, and expanding the sales team in anchor geographies. By 2027 and beyond, the company plans to scale revenue, move to a train-the-trainer model for implementation, expand clinical research opportunities, and grow the sales, clinical, and account management teams.
12-Lead Patch Development: The company has developed a working prototype of an on-demand 12-lead patch, which is expected to disrupt the $2 billion ambulatory cardiac monitoring market. A pilot clinical study in Europe is underway to demonstrate the patch's ability to detect ischemia. The study will enroll approximately 50 patients and will inform the regulatory strategy for the patch. Partnership discussions with industry players are ongoing to bring the patch to market.
Heart Attack Detection: The ALIGN-ACS pilot study in Europe is comparing the HeartBeam ECG to a standard 12-lead ECG for heart attack detection. Enrollment is ahead of schedule, and the study is expected to complete by the end of Q3 2026. The study will inform the design of an FDA pivotal study. The company is also developing AI algorithms for myocardial infarction (MI) detection, which will enhance the HeartBeam system's capabilities.
AI and Algorithm Development: The company is collaborating with Mount Sinai to develop next-generation AI algorithms for heart attack detection, wellness, and personalized cardiac assessment. These algorithms will be integrated into the HeartBeam system to provide insights on STEMI and NSTEMI heart attacks, enhancing physician interpretation and recommendations.
Financial Guidance: The company has reduced its cash outflow expectations for 2026 to below $16 million, down from the previously estimated $17-19 million. This provides funding into 2027 and supports the execution of critical milestones. The recent $11.5 million financing strengthens the financial position and extends the cash runway.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about how many patients are collectively managed by the two anchor partners and provide updates on pricing?
A:The number of patients managed by the anchor partners is not publicly shared, but the focus is on targeting 150,000 patients in the preventative concierge market, aiming for 30,000 patients to reach the breakeven point. The four markets represent tens of thousands of patients. Pricing is in the $750 to $1,000 annual subscription fee range, with no pushback received so far.
Q:What is the status of the ALIGN-ACS pilot study and the timing for the pivotal study?
A:The ALIGN-ACS pilot study involves 100-120 patients and is ahead of schedule, with enrollment expected to complete by the end of Q3. The study design is informing discussions with the FDA for the pivotal study design. No further timing updates are available yet.
Q:How will the HEADSTART-ACS study differ from ALIGN-ACS in terms of design and patient numbers?
A:The HEADSTART-ACS study has a similar design to ALIGN-ACS, focusing on ER chest pain patients and comparing it to a 12-lead ECG. It will involve around 500 patients and is sponsored by the Government of Indonesia, which is covering most of the costs. The study will also help validate the upcoming AI algorithm.
Q:How should revenue from subscription billing be modeled, and what is a realistic revenue expectation for 2026?
A:Revenue will be largely straight-lined over the year, with a slight higher portion recognized early in the contract due to onboarding costs. Most customers are expected to pay upfront for the first year. For 2026, early accounts with 400-4,000 patients could generate $750,000 to $1 million per account, assuming 50% adoption. The breakeven point is 30,000 patients, with a two-year pathway to achieve this.
Q:What does full adoption look like in a single practice, and what revenue can a fully penetrated flagship account generate annually?
A:Full adoption involves onboarding new and existing patients, as well as attracting new patients due to the technology. Early accounts have 400-4,000 patients, with 500-1,000 expected to adopt the technology, generating $750,000 to $1 million annually per account. More detailed data will be shared in August.
Q:Do you plan to produce television commercials to promote the product?
A:There are no plans for direct-to-consumer campaigns due to their high cost. The strategy focuses on targeting high-net-worth individuals through specific practices. Some prominent patients may organically promote the product, but the current B2B model is considered the most efficient growth strategy.
Q:Why did management not raise funds after approval and instead waited until the price was under $1?
A:Financing decisions were influenced by shareholder feedback, existing commitments, and the need to attract long-term investors. The recent funding deal was clean, involving only common stock, and brought strong partners on board. Management aims to execute milestones to improve valuation.
Q:Do you expect Q2 revenue?
A:Some revenue and cash from customers are expected in Q2, but the focus remains on securing the right partners and proving deep adoption. Significant revenue scaling is anticipated in the second half of the year.
Q:What feedback have medical professionals provided about the product, and how does it compare to traditional 12-lead systems?
A:Medical professionals appreciate the ability to provide patients with medical-grade technology for anytime, anywhere use. The product offers more frequent and detailed measurements compared to traditional 12-lead systems, which are typically used in clinical settings. There is interest in longitudinal data analysis, which has not been possible before.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numbers for the total patients managed by anchor partners, citing privacy concerns. They also did not provide detailed revenue projections for 2026 or specific adoption metrics for flagship accounts, promising more data in August. Additionally, no clear timeline was given for the pivotal study following ALIGN-ACS.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACS pilot
AI algorithm
ALIGN ACS
Atelier
ClearCardio
Dallas
ECG lead
HeartBeam patch
MI
New York
Sinai
South Florida
ability
anchor
attack detection
card patch
cash outflow
chest pain
demand lead
detection AI
emergency
financing
flagship
form factor
implementation
lead ECG
lead patch
monitoring
offering
patch card
patient chest
phase
pilot study
procedure
proceeds
runway
study HeartBeam
workflow
BEAT Transcript
HeartBeam, Inc. (BEAT) Q1 2026 Earnings Call Transcript
Positive5-14
The earnings call summary reveals strong financial discipline, a strategic focus on high-net-worth markets, and promising product development with AI collaborations. Despite some uncertainty in patient numbers and study timelines, the Q&A indicates positive sentiment towards the subscription model and revenue potential. The recent financing strengthens the company's financial position. The overall sentiment is positive, with expectations of reaching breakeven and significant revenue scaling, suggesting a stock price increase of 2-8% over the next two weeks.
HeartBeam, Inc. (BEAT) Q4 2025 Earnings Call Transcript
Unknown3-12
The company's financial performance shows a decline in revenue, which is negative, but they have strong cash reserves. The strategic plan highlights potential growth through FDA approvals and partnerships, which is positive. The Q&A reveals some uncertainties in regulatory paths and timelines, which could cause concern. Overall, the mixed signals from financials, strategic growth plans, and uncertainties result in a neutral sentiment.
HeartBeam, Inc. (BEAT) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call reveals a mixed sentiment. While there are positive developments like productive FDA discussions and strategic partnerships, concerns arise due to limited cash reserves and lack of detailed guidance on pricing and funding. The Q&A reflects cautious optimism but lacks clarity on key issues. The strategic focus on capital efficiency and market expansion is positive, yet the absence of immediate revenue growth and the need for further funding temper expectations. Given these factors, a neutral stock price movement is anticipated over the next two weeks.
HeartBeam, Inc. (BEAT) Q2 2025 Earnings Call Transcript
Unknown8-13
The earnings call presented a mixed picture: positive aspects include a decrease in operating cash use and progress towards FDA clearance, but concerns arise from the need for additional funding and lack of detailed guidance on strategic partnerships and pricing. The Q&A section did not reveal major risks but highlighted uncertainties around commercialization timelines and partnerships. The neutral sentiment stems from balancing these positive and negative elements, with no strong catalyst for significant stock movement.
BEAT Slides
BEAT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
